Related Experiment Video

Updated: Aug 16, 2026

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice
05:08

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice

Published on: October 3, 2019

Cardiac risk stratification in patients with congestive heart failure: a catecholamines-beta-adrenoceptor-cAMP

Ying-Xin Peng1, Jiang Shan, Su-jun Zhang

  • 1Department of Cardiology, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou. upls01@hotmail.com

Chinese Medical Sciences Journal = Chung-Kuo I Hsueh K'O Hsueh Tsa Chih
|August 4, 2005
PubMed

Insights

Persistent high levels of catecholamines and cAMP in congestive heart failure (CHF) patients predict increased cardiogenic death risk. Monitoring these markers may improve long-term mortality prediction in CHF.

Area of Science:

  • Cardiology
  • Biochemistry
  • Molecular Biology

Background:

  • Congestive heart failure (CHF) is associated with neurohormonal dysregulation.
  • The catecholamine-beta-adrenoceptor (beta-AR)-cAMP pathway plays a role in cardiovascular function and disease progression.

Purpose of the Study:

  • To evaluate the prognostic value of the catecholamine-beta-AR-cAMP pathway in predicting cardiogenic death in CHF patients.
  • To determine if persistent elevations in catecholamines and cAMP levels stratify risk for adverse cardiovascular events.

Main Methods:

  • A cohort of 83 CHF patients were monitored for plasma norepinephrine (NE) and epinephrine (E) levels, lymphocyte beta-AR density, and intralymphocyte cAMP content.
  • Patients were followed for major cardiogenic death events over a mean period of 65 months.

Main Results:

  • Persistent high levels of NE, E, and intralymphocyte cAMP were significant predictors of cardiogenic death.
  • Elevated NE (>4.0 nmol/L), E (>3.5 nmol/L), and cAMP (>3.5 pmd x mg(-1) x pro(-1)) were associated with significantly higher rates of cardiogenic death.
  • No significant difference in mortality was observed based on beta-AR density levels.

Conclusions:

  • Persistent increases in circulating catecholamines and intralymphocyte cAMP are associated with increased long-term mortality in CHF patients.
  • These markers may serve as valuable tools for risk stratification in CHF management.
Abstract

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...